HNSA fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Hansa Biopharma AB focuses on novel immunomodulatory enzymes, which treat rare immunoglobulin G-mediated autoimmune conditions, transplant rejection and cancer. Its pipeline includes IdeS, HBP-assay, EnzE, and NiceR. The company was founded by Lars Björck and Bo Krister Håkansson in 2001 and is headquartered in Lund, Sweden.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
HNSA does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company